[Federal Register Volume 60, Number 51 (Thursday, March 16, 1995)]
[Notices]
[Page 14291]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-6446]



-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary


Correction of Notice of Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Correction.

-----------------------------------------------------------------------

SUMMARY: A Notice beginning on page 10588 in the issue of February 27, 
1995, entitled ``Findings of Scientific Misconduct'' is hereby 
reprinted in its entirety because of an omission in the original 
printing:
    Vivian N. Tanner, Cleveland Clinic Foundation: The Division of 
Research Investigations of the Office of Research Integrity (ORI) 
conducted an investigation into possible scientific misconduct on the 
part of Vivian N. Tanner while she was a clinic coordinator for the 
Collaborative Ocular Melanoma Study (COMS) at the Cleveland Clinic 
Foundation (CCF). ORI concluded that Ms. Tanner committed scientific 
misconduct by falsifying and fabricating clinical trial data on 
research data forms related to a multicenter study on the treatment of 
choroidal melanoma, a rare form of eye cancer. Due to these 
falsifications and fabrications, inaccurate clinical data were entered 
into the clinical trial database. These acts were committed over a 
period of several years, were material, and, therefore, were 
potentially detrimental to the study. The CCF COMS project has received 
U.S. Public Health Service support from 1985 to the present through 
subcontract funds from a National Eye Institute cooperative agreement 
award to the COMS Coordinating Center, The Wilmer Ophthalmological 
Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland. 
Ms. Tanner has been debarred from eligibility for and involvement in 
grants as well as other assistance awards and contracts from the 
Federal Government for a period of three years. Because the COMS is an 
ongoing study, no publications were affected by the falsified or 
fabricated data, and no clinical treatment has been based on the 
results of the study.

FOR FURTHER INFORMATION, CONTACT: Director, Division of Research 
Investigations, Office of Research Integrity, 301-443-5330.
Lyle W. Bivens, Ph.D.,
Director, Office of Research Integrity.
[FR Doc. 95-6446 Filed 3-15-95; 8:45 am]
BILLING CODE 4160-17-P